The Hexa-LPS Index: An Estimate of Microbial Endotoxin Potential

The Hexa-LPS index and endotoxin signaling

Lipopolysaccharides, or LPS, form part of the outer membrane of Gram-negative bacteria. Their structure affects how they interact with the immune system. A Hexa-LPS index aims to estimate, from microbiome data, the potential for certain forms of lipid A with six acyl chains. These forms can strongly activate the TLR4 receptor, while other structures act differently or less strongly. The number of acyl chains is not the only factor that determines the response.

The stool-based score described here is inferred from organisms or genes detected through sequencing. A 16S-based assignment and a metagenomic gene analysis draw on different information. The score models a possible microbial capability; it does not directly measure LPS in the blood or a person’s actual TLR4 activation. A particular provider’s calculation and validation need to be examined separately.

Diet, medicines and illness can change the microbial community, and models vary between providers. A precise-looking number should not be mistaken for a precise measurement of systemic inflammation.

Why scientists study LPS structure

Microbes and the immune system exchange signals continuously. LPS is among the most closely studied bacterial molecules. Some microbial communities may have greater potential to produce strongly immune-stimulating LPS forms. How much crosses the gut barrier, and what it does in the body, are additional questions.

Research on different types of lipopolysaccharide explores links with metabolic health and endotoxin signaling. The cited experiments compared effects of different LPS preparations in mice; they did not validate a commercial stool score in people. They do not establish that tiredness after meals, skin symptoms or difficulty concentrating are caused by a high Hexa-LPS index. Those symptoms are nonspecific and need consideration in their own right.

Why someone might be interested in the result

Common reasons for interest include:

• persistent bloating or changing food tolerance;
• changes after antibiotics, restrictive eating or illness;
• questions about glucose, blood lipids or body composition;
• plans to introduce more fiber, polyphenols or fermented foods;
• curiosity about how a personal profile compares with reference groups.

These are possible interests, not established medical indications for the index. Before testing, it is worth identifying which decision the result could improve. A score without a validated consequence can add uncertainty without improving care.

How to read the index

Reports may show an index or estimated proportion, together with the organisms and pathways that influence it. Certain Enterobacteriaceae can increase the modeled potential for hexa-acylated LPS. A different community may produce a lower score. Reference ranges depend on the population, method and model.

A low index does not confirm an intact gut barrier or adequate butyrate production. A high index does not prove endotoxin absorption, greater systemic TLR4 activation or disease. Those conclusions would require additional measurements and clinically validated interpretation.

Low diversity combined with a high score is, first of all, a pattern in the data. It may suggest research questions, but cannot reliably explain bloating, tiredness or inflammation. Read a label such as “optimal” as a provider-specific category.

What can shift the result?

Several influences matter:

• Recent food intake can change relative abundances.
• Antibiotics and other medicines affecting the gut can alter composition and detectability.
• Travel, infections and changes in routine may cause temporary shifts.
• Stool consistency and transit time influence the sample.
• Storage and DNA processing affect the technical yield.
• Different sequencing and calculation methods do not necessarily produce comparable scores.

A difference between two tests can therefore have several explanations. It does not prove that the most recently started intervention reduced an “inflammatory burden.”

What other information might help?

Measures discussed alongside the index include diversity, predicted fatty-acid pathways, LPS-binding protein, or LBP, soluble CD14, hs-CRP, glucose, HbA1c and blood lipids. They reflect different processes. LBP and soluble CD14 are not simple, specific gauges of endotoxin exposure originating only in the gut. hs-CRP is nonspecific too.

Whether additional tests are useful depends on a medical question. A food and symptom record may be more directly useful for understanding personal tolerance. An unusual index alone is not a reason to order a broad laboratory package.

What the Hexa-LPS index can and cannot do

It describes a modeled capability of the sampled community. It does not measure circulating endotoxin or intestinal permeability, and it cannot diagnose a disease or reliably predict its course. Repeat testing can document a change in the model’s output; its clinical usefulness is a separate question.

Frequently asked questions

What does the Hexa-LPS test measure?

It estimates certain LPS-producing capabilities from taxonomic or genetic data. The calculation should be transparent. This does not automatically include direct measurement of LPS structure, its concentration in blood or the immune response.

How is the sample collected?

Usually with a home stool collection kit. Clean collection, correct labeling, preservation and shipping according to laboratory instructions all matter. Any additional blood markers are separate tests.

What can it tell me about my health?

The result can describe a research model of microbial interactions with the immune system. It cannot reliably explain an individual’s skin problems, exhaustion, food reactions or metabolic disorders. Symptoms need a medical assessment independent of the score.

How reliable is the index?

Alongside the usual sources of sequencing error, it contains assumptions about organisms and their LPS. The accuracy of a DNA measurement does not automatically carry over to the health interpretation derived from it. Comparability between providers should not be assumed.

How often should it be measured?

There is no established routine interval. Annual testing, or testing every three to six months, is not a general preventive-care rule. Repeating the test is useful only when its purpose and possible consequences are clear.

Can the index change quickly?

Yes, if the sampled community or the sample changes. The trend describes a calculated property of the community, not the size of one population. A rapid decline does not prove an equally rapid fall in systemic inflammation.

Is a high result diagnostic?

No. It does not diagnose “leaky gut,” endotoxemia, food intolerance or another condition. Those labels should not be assigned from the score alone.

What can I do after an unusual result?

Overall diet quality, fiber you tolerate, activity and sleep can be worthwhile goals regardless of the score. It does not establish a particular probiotic, prebiotic or supplement treatment. If you have symptoms, clarify the clinical question first instead of treating an isolated model output.

Sources

• Anhê FF, Barra NG, Cavallari JF, Henriksbo BD, Schertzer JD (2021). Metabolic endotoxemia is dictated by the type of lipopolysaccharide. Cell Reports, 36(11), 109691. https://doi.org/10.1016/j.celrep.2021.109691 PubMed

• Martirosyan A, Ohne Y, Degos C, Gorvel L, Moriyón I, Oh S, Gorvel JP (2013). Lipopolysaccharides with acylation defects potentiate TLR4 signaling and shape T cell responses. PLOS ONE, 8(2), e55117. https://doi.org/10.1371/journal.pone.0055117 PubMed

• Mann ER, Lam YK, Uhlig HH (2024). Short-chain fatty acids: Linking diet, the microbiome and immunity. Nature Reviews Immunology, 24(8), 577-595. https://doi.org/10.1038/s41577-024-01014-8 PubMed

• Lynch SV, Pedersen O (2016). The human intestinal microbiome in health and disease. New England Journal of Medicine, 375(24), 2369-2379. https://doi.org/10.1056/NEJMra1600266 PubMed

• Allaband C, McDonald D, Vázquez-Baeza Y, Minich JJ, Tripathi A, Brenner DA, Loomba R, Smarr L, Sandborn WJ, Schnabl B, Dorrestein P, Zarrinpar A, Knight R (2019). Microbiome 101: Studying, analyzing, and interpreting gut microbiome data for clinicians. Clinical Gastroenterology and Hepatology, 17(2), 218-230. https://doi.org/10.1016/j.cgh.2018.09.017 PubMed